New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
12:07 EDTNUS, HLF, P, AAPL, ARWR, ISIS, GILD, UPSOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday following reports on the state of manufacturing in the U.S., China and the European Union. The Purchasing Managers' Indexes, or PMIs, showed that manufacturing activity contracted last month in China but that it had expanded again in the U.S. and the EU. ECONOMIC EVENTS: In the U.S., Markit's manufacturing PMI for March fell to 55.5 from February's 57.1 reading. The reading was 1 point below the consensus forecast, but was still strongly in expansionary territory, as 50 is the dividing line between expansion and contraction. In China, Markit's flash PMI came in at 48.1, falling short of expectations for a 48.7 reading. In Europe, the PMI for the euro area as a whole came in at 53.2, which was just below last month's 32-month high reading of 53.3. COMPANY NEWS: Shares of Nu Skin Enterprises (NUS) surged nearly 19% near midday after the company's China business was penalized only $540,000 for direct sales of certain products. Nu Skin said it is already taking steps to correct the issues raised in the AIC reviews and that it is not aware of any other material enforcement investigations currently pending in China. Research firm Deutsche Bank said it expects Nu Skin to announce a "significant" share repurchase program over the next several quarters after the China investigation was resolved with "modest" fines. Deutsche thinks today's news lifts an overhang on Nu Skin and keeps a Buy rating on the stock with a $110 price target. Meanwhile shares of Nu Skin's multi-level marketing peer Herbalife (HLF), which has also been accused of impropriety in China, are up about 8%. Herbalife had its own news this morning as well, as it announced that it has amended and restated its agreement with Carl Icahn and will nominate three new Icahn designees for election to the company’s board. MAJOR MOVERS: Among the notable gainers was MicroVision (MVIS), which jumped 20% after announcing that it has agreed to supply customized PicoP display modules to shipping giant UPS (UPS). Also higher was Symantec (SYMC), which rose 2% after research firm BMO Capital upgraded the stock and said it believes all strategic options, including a sale or divestiture of underperforming assets, will be considered following the company's recent termination of its CEO. Among the noteworthy losers was Arrowhead Research (ARWR), which dropped more than 15%. Research firm Piper Jaffray attributed the move lower to competitor ISIS Pharmaceuticals (ISIS) having announced preclinical data on its own antisense compound targeting hepatitis B virus, which is a clinical area that Arrowhead is also exploring. A number of other biotechnology companies' shares were also lower, with Oppenheimer attributing the continued weakness in the sector to investor concerns that were sparked by a letter sent Friday by several members of Congress to Gilead (GILD) regarding the price of its Hepatits C drug, Sovaldi. Also lower were shares of Internet radio company Pandora (P), which slid almost 9% after Billboard reported on Friday that Apple (AAPL) is considering launching a new music service and is also weighing a new iTunes app for Android smartphones. INDEXES: Near midday, the Dow was down 52.55, or 0.32%, to 16,250.22, the Nasdaq was down 66.01, or 1.54%, to 4,210.78, and the S&P 500 was down 12.25, or 0.66%, to 1,854.27.
News For NUS;HLF;P;AAPL;ARWR;ISIS;GILD;UPS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | all recent news | >>
October 10, 2014
17:57 EDTAAPLGT Advanced calls Apple demands 'burdensome, oppressive,' Bloomberg reports
Subscribe for More Information
17:14 EDTAAPLMarket ends week lower amid global growth worries
Subscribe for More Information
16:02 EDTAAPLActionable Options for Friday, October, 10
Subscribe for More Information
15:30 EDTAAPLApple, Bose settle patent infringement litigation, CNBC reports
Subscribe for More Information
14:08 EDTGILDGilead 12-week regimen of Harvoni to cost $94.5K
Gilead said its newly-approved treatment of hepatitis C genotype 1 infection, Harvoni, will be priced at $94,500 for a full 12 week regiment, according to multiple media outlets, which cite a company spokesperson.
13:55 EDTGILDGilead confirms FDA approval of Harvoni
Subscribe for More Information
13:42 EDTGILDGilead hepatitis C treatment Harvoni approved by FDA
The FDA announced the approval of Harvoni to treat chronic hepatitis C virus genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection, the agency stated. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection, it added. Harvoni is marketed by Gilead.
13:40 EDTGILDFDA approves Gilead hepatitus C treatment Harvoni
Subscribe for More Information
12:11 EDTARWR, HLFOptions with increasing implied volatility
Subscribe for More Information
11:27 EDTNUSPrescott General Patrners reports 4.3% passive stake in Nu Skin
Subscribe for More Information
10:55 EDTHLFHerbalife volatility increases
Subscribe for More Information
10:12 EDTAAPLApple to remove Bose products from retail stores, MacRumors reports
Subscribe for More Information
09:38 EDTAAPLActive equity options trading on open
Subscribe for More Information
09:00 EDTISISOn The Fly: Pre-market Movers
Subscribe for More Information
08:19 EDTGILDMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
07:39 EDTAAPLApple underappreciated but Icahn estimates aggressive, says UBS
Subscribe for More Information
07:21 EDTGILDFDA PDUFA Date for Gilead Sciences Sofosbuvir is October 10, 2014
Subscribe for More Information
07:08 EDTAAPLApple given at least 3 days to block info in GT bankruptcy case, Reuters says
Subscribe for More Information
07:04 EDTAAPLAmazon in talks to join digital locker for movies. WSJ reports
Subscribe for More Information
05:22 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx Phase 2 study
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use